|
1
|
Shaib YH, Davila JA and El-Serag B: The
epidemiology of pancreatic cancer in the United States: Changes
below the surface. Aliment Pharmacol Ther. 24:87–94. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rosenberg L: Pancreatic cancer: A review
of emerging therapies. Drugs. 59:1071–1089. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Freelove R and Walling AD: Pancreatic
cancer: Diagnosis and management. Am Fam Physician. 73:485–492.
2006.PubMed/NCBI
|
|
5
|
Bilimoria KY, Bentrem DJ, Ko CY, Stewart
AK, Winchester DP and Talamonti MS: National failure to operate on
early stage pancreatic cancer. Ann Surg. 246:173–180. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zuckerman DS and Ryan DP: Adjuvant therapy
for pancreatic cancer: A review. Cancer. 112:243–249. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rothenberg ML, Moore MJ, Cripps MC,
Andersen JS, Portenoy RK, Burris HA III, Green MR, Tarassoff PG,
Brown TD, Casper ES, et al: A phase II trial of gemcitabine in
patients with 5-FU-refractory pancreas cancer. Ann Oncol.
7:347–353. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Burris HA III, Moore MJ, Andersen J, et
al: Improvements in survival and clinical benefit with gemcitabine
as first-line therapy for patients with advanced pancreas cancer: A
randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
|
|
9
|
Mini E, Nobili S, Caciagli B, Landini I
and Mazzei T: Cellular pharmacology of gemcitabine. Ann Oncol.
17(Suppl 5): v7–v12. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schultz RM, Merriman RL, Toth JE,
Zimmermann JE, Hertel LW, Andis SL, Dudley DE, Rutherford PG,
Tanzer LR and Grindey GB: Evaluation of new anticancer agents
against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma
xenografts. Oncol Res. 5:223–228. 1993.PubMed/NCBI
|
|
11
|
Nakano Y, Tanno S, Koizumi K, Nishikawa T,
Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T and Kohgo
Y: Gemcitabine chemoresistance and molecular markers associated
with gemcitabine transport and metabolism in human pancreatic
cancer cells. Br J Cancer. 96:457–463. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu B, Guo X, Mathew S, Armesilla AL,
Cassidy J, Darling JL and Wang W: Triptolide simultaneously induces
reactive oxygen species, inhibits NF-kappaB activity and sensitizes
5-fluorouracil in colorectal cancer cell lines. Cancer Lett.
291:200–208. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qiu D, Zhao G, Aoki Y, Shi L, Uyei A,
Nazarian S, Ng JC and Kao PN: Immunosuppressant PG490 (triptolide)
inhibits T-cell interleukin-2 expression at the level of
purine-box/nuclear factor of activated T-cells and NF-kappaB
transcriptional activation. J Biol Chem. 274:13443–13450. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu Q: Triptolide and its expanding
multiple pharmacological functions. Int Immunopharmacol.
11:377–383. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brinker AM, Ma J, Lipsky PE and Raskin I:
Medicinal chemistry and pharmacology of genus Tripterygium
(Celastraceae). Phytochemistry. 68:732–766. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang W, He T, Chai C, Yang Y, Zheng Y,
Zhou P, Qiao X, Zhang B, Liu Z, Wang J, et al: Triptolide inhibits
the proliferation of prostate cancer cells and down-regulates
SUMO-specific protease 1 expression. PLoS One. 7:e376932012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Phillips PA, Dudeja V, McCarroll JA,
Borja-Cacho D, Dawra RK, Grizzle WE, Vickers SM and Saluja AK:
Triptolide induces pancreatic cancer cell death via inhibition of
heat shock protein 70. Cancer Res. 67:9407–9416. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shamon LA, Pezzuto JM, Graves JM, Mehta
RR, Wangcharoentrakul S, Sangsuwan R, Chaichana S, Tuchinda P,
Cleason P and Reutrakul V: Evaluation of the mutagenic, cytotoxic
and antitumor potential of triptolide, a highly oxygenated
diterpene isolated from Tripterygium wilfordii. Cancer Lett.
112:113–117. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li CJ, Chu CY, Huang LH, Wang MH, Sheu LF,
Yeh JI and Hsu HY: Synergistic anticancer activity of triptolide
combined with cisplatin enhances apoptosis in gastric cancer in
vitro and in vivo. Cancer Lett. 319:203–213. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen YW, Lin GJ, Chuang YP, Chia WT, Hueng
DY, Lin CK, Nieh S and Sytwu HK: Triptolide circumvents
drug-resistant effect and enhances 5-fluorouracil antitumor effect
on KB cells. Anticancer Drugs. 21:502–513. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu W, Li J, Wu S, Li S, Le L, Su X, Qiu
P, Hu H and Yan G: Triptolide cooperates with Cisplatin to induce
apoptosis in gemcitabine-resistant pancreatic cancer. Pancreas.
41:1029–1038. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y and Cui YF: Synergism of
cytotoxicity effects of triptolide and artesunate combination
treatment in pancreatic cancer cell lines. Asian Pac J Cancer Prev.
14:5243–5248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang SW, Wang W, Xie XY, Zhu WP and Li FQ:
In vitro synergistic cytotoxic effect of triptolide combined
with hydroxycamptothecin on pancreatic cancer cells. Am J Chin Med.
39:121–134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kiviharju TM, Lecane PS, Sellers RG and
Peehl DM: Antiproliferative and proapoptotic activities of
triptolide (PG490), a natural product entering clinical trials, on
primary cultures of human prostatic epithelial cells. Clin Cancer
Res. 8:2666–2674. 2002.PubMed/NCBI
|
|
25
|
Qiao Z, Ren S, Li W, Wang X, He M, Guo Y,
Sun L, He Y, Ge Y and Yu Q: Chidamide, a novel histone deacetylase
inhibitor, synergistically enhances gemcitabine cytotoxicity in
pancreatic cancer cells. Biochem Biophys Res Commun. 434:95–101.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Donadelli M, Costanzo C, Beghelli S,
Scupoli MT, Dandrea M, Bonora A, Piacentini P, Budillon A, Caraglia
M, Scarpa A and Palmieri M: Synergistic inhibition of pancreatic
adenocarcinoma cell growth by trichostatin A and gemcitabine.
Biochim Biophys Acta. 1773:1095–1106. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xie C, Edwards H, Xu X, Zhou H, Buck SA,
Stout ML, Yu Q, Rubnitz JE, Matherly LH, Taub JW and Ge Y:
Mechanisms of synergistic antileukemic interactions between
valproic acid and cytarabine in pediatric acute myeloid leukemia.
Clin Cancer Res. 16:5499–5510. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xiang M, Qian ZY, Zhou CH, Liu J and Li
WN: Crocetin inhibits leukocyte adherence to vascular endothelial
cells induced by AGEs. J Ethnopharmacol. 107:25–31. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kinnally KW and Antonsson B: A tale of two
mitochondrial channels, MAC and PTP, in apoptosis. Apoptosis.
12:857–868. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dai Y and Grant S: New insights into
checkpoint kinase 1 in the DNA damage response signaling network.
Clin Cancer Res. 16:376–383. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kupchan SM, Court WA, Dailey RG
Jr..Gilmore CJ and Bryan RF: Triptolide and tripdiolide, novel
antileukemic diterpenoid triepoxides from Tripterygium
wilfordii. J Am Chem Soc. 94:7194–7195. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hu YP, Tan ZJ, Wu XS, Liu TY, Jiang L, Bao
RF, Shu YJ, Li ML, Weng H, Ding Q, Tao F and Liu YB: Triptolide
induces s phase arrest and apoptosis in gallbladder cancer cells.
Molecules. 2014.19(2): 2612–2628. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ho JN, Byun SS, Lee S, Oh JJ, Hong SK, Lee
SE and Yeon JS: Synergistic antitumor effect of triptolide and
cisplatin in cisplatin resistant human bladder cancer cells. The
Journal of urology. 2015.193(3): 1016–1022, 14. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chueh FS, Chen YL, Hsu SC, Yang JS, Hsueh
SC, Ji BC, Lu HF and Chung JG: Triptolide induced DNA damage in
A375.S2 human malignant melanoma cells is mediated via reduction of
DNA repair genes. Oncol Rep. 29:613–618. 2013.PubMed/NCBI
|
